Strategy

Turning Cold Tumors Hot | Ep. 985

A Strategic & Technical Roadmap

19 hrs ago

Biotech’s Imitation Crisis | Ep. 981

Why Playing It Safe Could Kill You

Apr 12

The Compounding Power of Outliers | Ep. 976

How US VC Exits Are Evolving

Apr 5

Trial by Design | Ep. 971

What Neuroscience Can Teach Oncology, Autoimmune, and Cardiometabolic Drug Development

Mar 29

The Mega-Round Mirage | Ep. 965

How Mega-Rounds Are Reshaping Biotech Venture Capital

Mar 22

Financing strategy for early stage biotech | Ep. 959

Rethinking Financing Strategies for Early Stage Biotech Companies

Mar 15 • BowTiedBiotech

New target discovery I&I | Ep. 953

Mar 8

The Illusion of Movement | Ep. 947

Why Biotech Stocks Aren’t Going Anywhere Without Real Liquidity

Mar 1

The Extinction of Diversified Pharma | Ep. 941

Focus wins. Ruthless portfolio prioritization is the new biotech moat.

Feb 23

5 Hidden Themes Driving China’s Biotech Surge | Ep. 934

...and 5 Bold Predictions for What’s Next

Feb 16

The $1 Billion Shortcut | Ep. 928

How One Radiopharma Play Unlocked the New Playbook for Biotech Company Creation

Feb 6

Using LLMs to Identify Successful Founder Phenotypes and Beyond | Ep. 921

When language models start beating the best VCs at their own game

Feb 1

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts